Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Clinical Chemistry

• Publication date

  1999-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1093/clinchem/45.8.1240PMID 10430790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Malignant hypercalcemia--a hospital survey.

  2009cited by this paper
• Assessment of renal and skeletal components of hypercalcemia

  2007cited by this paper
• The value of biomarkers in detecting alterations in bone metabolism

  2007cited by this paper
• BIOCHEMICAL MARKERS OF BONE TURNOVER

  1998cited by this paper
• Skeletal complications of malignancy

  1997cited by this paper
• Comparison of Assay of Total and Bone-Specific Alkaline Phosphatase in the Assessment of Osteoblast Activity in Patients with Metastatic Bone Disease

  1997cited by this paper
• Tumor‐induced hypercalcemia and parathyroid hormone‐related protein in lung carcinoma

  1996cited by this paper
• Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma.

  1996cited by this paper
• Metabolic effects of pamidronate in patients with metastatic bone disease.

  1996cited by this paper
• Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.

  1996cited by this paper
• Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.

  1996cited by this paper
• Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.

  1996cited by this paper
• Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease

  1995cited by this paper
• Bone and cancer: pathophysiology and treatment of metastases.

  1995cited by this paper
• Biochemical picture of bone metabolism in breast cancer patients with bone metastases.

  1995cited by this paper
• Biochemical markers of bone turnover in patients with metastatic bone disease.

  1995cited by this paper
• The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease.

  1995cited by this paper
• Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease.

  1995cited by this paper
• Evaluation of bone disease in breast cancer

  1994cited by this paper
• Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.

  1994cited by this paper
• Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate).

  1994cited by this paper
• Pathogenesis and management of cancer associated hypercalcaemia.

  1994cited by this paper
• Distinction between focally accelerated bone formation and osteomalacia in carcinoma of prostate metastasised to bone.

  1993cited by this paper
• Osteoclast inhibition for the treatment of bone metastases.

  1993cited by this paper
• Levels of Parathyroid Hormone-Related Protein (PTHrP) in Hypercalcemia of Malignancy Are not Lowered by Treatment With the Bisphosphonate BM 21.0955

  1993cited by this paper
• Palliative pamidronate treatment in patients with bone metastases from breast cancer.

  1993cited by this paper
• Increased urinary excretion of pyridinium cross-links in cancer patients.

  1993cited by this paper
• Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center

  1993cited by this paper
• Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group.

  1993cited by this paper
• Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.

  1993cited by this paper
• Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation.

  1993cited by this paper
• Bone destruction in cancer.

  1993cited by this paper
• Transient increase in total serum alkaline phosphatase predicts radiological response to systemic therapy in breast cancer patients with osteolytic and mixed bone metastases.

  1993cited by this paper
• Bone destruction in cancer.

  1993cited by this paper
• Biochemical markers of bone turnover

  1993cited by this paper
• Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma.

  1992cited by this paper
• Malignant bone resorption: cellular and biochemical mechanisms.

  1992cited by this paper
• Alkaline phosphatase isoenzyme patterns in malignant disease.

  1992cited by this paper
• Rationale for the use of bisphosphonates in bone metastases.

  1991cited by this paper
• Pyridinium crosslinks as markers of bone resorption in patients with breast cancer.

  1991cited by this paper
• Hyperparathyroidism in metastases of prostatic carcinoma: a biochemical, hormonal and histomorphometric study.

  1990cited by this paper
• Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

  1988cited by this paper
• Distinguishing features of primary hyperparathyroidism in patients with breast cancer

  1987cited by this paper
• Bone metastases in breast cancer, prostate cancer and myeloma.

  1987cited by this paper
• Bone metastases in breast cancer, prostate cancer and myeloma.

  1987cited by this paper
• Generalised increase in bone resorption in carcinoma of the prostate.

  1985cited by this paper
• An evaluation of

  1983cited by this paper
• Statistical package for the social sciences (spss)

  1981cited by this paper
• Relation between serum and urinary calcium with particular reference to parathyroid activity.

  1969cited by this paper
• 0163-769X/98/$03.00/0 Endocrine Reviews 19(1): 18–54 Copyright © 1998 by The Endocrine Society Printed in U.S.A. Cancer and Bone*

  year unknowncited by this paper

• Relationship Between Urinary 6‐Sulfatoxymelatonin Rhythms and the Bone Resorption Marker Amino‐Terminal Cross‐Linked Telopeptide of Collagen I in Blind Women

  2025cites this paper
• Outcomes and complications of organ-sparing treatment of patients with tumor and tumor-like conditions of the forearm long bones

  2022cites this paper
• Effects of palliative radiotherapy and bisphosphonate usage on bone turnover marker levels in cancer patients with osteolytic bone metastases

  2021cites this paper
• "The use of bisphosphonates to treat skeletal complications in solid tumours".

  2021cites this paper
• Changes in serological bone turnover markers in bisphosphonate induced osteonecrosis of the jaws: A case control study

  2020cites this paper
• Detection and Characterization of Musculoskeletal Cancer Using Whole-Body Magnetic Resonance Imaging

  2020cites this paper
• Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE

  2020cites this paper
• Diet and Lifestyle in Prostate Cancer.

  2019cites this paper
• [Predictive factors for skeletal-related events in lung cancer].

  2019cites this paper
• Prostate Cancer: Cellular and Genetic Mechanisms of Disease Development and Progression

  2019cites this paper
• Bone-targeted therapies to reduce skeletal morbidity in prostate cancer

  2018cites this paper
• Theranostic approach in lung cancer bone metastases.

  2018cites this paper
• Endothelin signaling regulates mineralization and posttranscriptionally regulates SOST in TMOb cells via miR 126‐3p

  2017cites this paper
• Endothelin Signaling in Bone.

  2017cites this paper
• Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer

  2017cites this paper
• Relationship between melatonin and bone resorption rhythms in premenopausal women

  2017cites this paper
• WITHDRAWN: Endothelin signaling in bone.

  2016cites this paper
• The utility of bone remodeling markers in the diagnosis, evolution and treatment response evaluation in bone metastases.

  2016cites this paper
• Osteoporosis during the hormonal therapy of prostate cancer and markers of bone tissue remodeling

  2016cites this paper
• Refractory hypocalcaemia complicating metastatic prostatic carcinoma

  2015cites this paper
• Early Outcomes of Reverse Shoulder Arthroplasty for Tumors of the Humerus

  2015cites this paper
• Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer

  2015cites this paper
• Diagnostic and prognostic validity of serum bone turnover markers in bone metastatic non-small cell lung cancer patients

  2015cites this paper
• Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis

  2015cites this paper
• Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study.

  2015cites this paper
• Chapter 12 – Bone remodeling markers and bone cancer

  2015cites this paper
• ЭНДОПРОТЕЗИРОВАНИЕ ПЛЕЧЕВОГО СУСТАВА ПРИ ОПУХОЛЕВОМ ПОРАЖЕНИИ ПРОКСИМАЛЬНОГО ОТДЕЛА ПЛЕЧЕВОЙ КОСТИ

  2015cites this paper
• Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV Lung Cancer—CSP-HOR 13

  2014cites this paper
• Bone resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulin-like growth factor and hypoxia

  2014cites this paper
• Calcium and phosphorus intake and prostate cancer risk : a 24-y follow-up study 1 – 3

  2014cites this paper
• [National consensus of diagnosis and treatment of non-small cell lung cancer].

  2013cites this paper
• Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments

  2013cites this paper
• Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.

  2013cites this paper
• Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.

  2013cites this paper
• Chronic administration of the selective P2X3, P2X2/3 receptor antagonist, A-317491, transiently attenuates cancer-induced bone pain in mice.

  2012cites this paper
• Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal‐related events in patients with prostate cancer with bone metastasis

  2012cites this paper
• The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer

  2012cites this paper
• Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer.

  2012cites this paper
• Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation.

  2012cites this paper
• Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases.

  2011cites this paper
• P2X7 receptor‐deficient mice are susceptible to bone cancer pain

  2011cites this paper
• Consensus on the utility of bone markers in the malignant bone disease setting.

  2011influential citation
• ICTP in bone metastases of lung cancer.

  2011cites this paper
• Serum N-Terminal Propeptide of Collagen Type I is Associated with the Number of Bone Metastases in Breast and Prostate Cancer and Correlates to Other Bone Related Markers

  2011cites this paper
• Clinical application value of bone turnover markers in non-small-cell lung cancer patients with bone metastases

  2011cites this paper
• Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data.

  2011cites this paper
• Bone turnover markers: Tools for prognosis and monitoring response to bisphosphonates?

  2011cites this paper
• 骨代谢标志物ICTP、BAP对肺癌骨转移的诊断意义

  2010cites this paper
• Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases

  2010cites this paper
• Comparative Review of Denosumab Versus Zoledronic Acid for the Reduction or Delay of Serious Complications Associated with Bone Metastases of Breast Cancer

  2010cites this paper
• Bone Remodeling Markers and Bone Cancer

  2010cites this paper
• Pattern of skeletal metastases from breast cancer in an Asian population

  2010cites this paper
• La périostine, un nouveau biomarqueur des métastases osseuses : développement d’un immunodosage et évaluation préclinique

  2010cites this paper
• Differential contributions of host-derived matrix metalloproteinases in mammary tumor growth in the bone microenvironment

  2009cites this paper
• Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation

  2009cites this paper
• Die Rolle der Knochenumbaumarker bei Knochenmetastasen

  2009cites this paper
• RANKL inhibition in the treatment of bone metastases

  2008cites this paper
• [Bone metastases in lung cancer].

  2008cites this paper
• Targeting the receptor activator of nuclear factor‐κB (RANK) ligand in prostate cancer bone metastases

  2008cites this paper
• Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity

  2008cites this paper
• Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease

  2008cites this paper
• The use of molecular markers of bone turnover in the management of patients with metastatic bone disease

  2008cites this paper
• Histopathological assessment of prostate cancer bone osteoblastic metastases.

  2008cites this paper
• Skeletal Complications: Bone Metabolism and Novel Targeted Agents

  2008cites this paper
• Does increased local bone resorption secondary to breast and prostate cancer result in increased cartilage degradation?

  2008cites this paper
• Prostate Cancer, Serum Parathyroid Hormone, and the Progression of Skeletal Metastases

  2008cites this paper
• Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases

  2008cites this paper
• TITLE : Castration Induced Neuroendocrine Mediated Progression of Prostate Cancer PRINCIPAL INVESTIGATOR :

  2007influential citation
• Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.

  2007cites this paper
• Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.

  2007cites this paper
• The central role of osteoblasts in the metastasis of prostate cancer

  2007cites this paper
• The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.

  2007cites this paper
• Short-term effects of pamidronate on bone turnover: can bone markers be considered predictive of the analgesic response?

  2007cites this paper
• Pharmacokinetics and pharmacodynamics of a single dose of zoledronate in healthy dogs.

  2007cites this paper
• Predictive value of osteocalcin and β-CrossLaps in metastatic breast cancer

  2007cites this paper
• Urine calcium and deoxypyridinoline in assessment of response to local radiation therapy for metastatic bone disease.

  2007cites this paper
• Award Number: W81XWH-04-1-0818 TITLE: Castration Induced Neuroendocrine Mediated Progression of Prostate Cancer

  2007cites this paper
• Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer.

  2007cites this paper
• Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications

  2007cites this paper
• The Relative Use of Eight Collagenous and Noncollagenous Markers for Diagnosis of Skeletal Metastases in Breast, Prostate, or Lung Cancer Patients

  2006cites this paper
• Natural history and treatment of bone complications in prostate cancer.

  2006cites this paper
• Markers of bone metabolism in prostate cancer.

  2006cites this paper
• Markers of bone formation and resorption in patients with mixed subtype osteosarcoma

  2006cites this paper
• Metastatic bone disease

  2006cites this paper
• Chapter 16 – Sex Steroids and Skeletal Health in Men

  2006cites this paper
• Human mesenchymal stem cell derived osteoblasts degrade organic bone matrix in vitro by matrix metalloproteinases.

  2005cites this paper
• Usefulness of Bone Formation Markers in Breast Cancer

  2005cites this paper
• New therapeutic agents for the treatment of bone diseases

  2005cites this paper
• PINP as serum marker of metastatic spread to the bone in breast cancer patients.

  2005cites this paper
• Usefulness of bone formation markers in breast cancer.

  2005cites this paper
• Evaluation of pain-related behavior, bone destruction and effectiveness of fentanyl, sufentanil, and morphine in a murine model of cancer pain.

  2005cites this paper
• Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

  2005cites this paper
• Bone turnover markers and bone scintigraphy in the evaluation of the skeletal metastases.

  2005cites this paper
• Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

  2005cites this paper
• Clinical use of markers of bone turnover in metastatic bone disease

  2005cites this paper
• Utility of Type I Collagen-Derived Markers as Reflectors of Bone Turnover in Different Clinical Situations

  2004cites this paper
• Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.

  2004cites this paper
• Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors.

  2003cites this paper
• Bone Cancer Pain

  2003cites this paper
• Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities

  2003cites this paper